Text Size

Invasive Fungal Infections Surveillance Initiative

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177944
First received: September 13, 2005
Last updated: January 15, 2013
Last verified: January 2013
History of Changes

September 13, 2005
January 15, 2013
August 2005
August 2012   (final data collection date for primary outcome measure)
outcome after invasive fungal infection [ Time Frame: 60 days post infection ] [ Designated as safety issue: No ]
outcome after invasive fungal infection
Not Provided
Complete list of historical versions of study NCT00177944 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Invasive Fungal Infections Surveillance Initiative
Invasive Fungal Infections Surveillance Initiative

The purpose of this study is to optimize the management of patients treated for invasive fungal infections by establishing a real-time, continuous clinical data base that will capture and monitor trends in the epidemiology, diagnosis, treatment and outcomes of invasive fungal infections; reflect routine clinical management of patients with invasive fungal infections in order to evaluate treatment and provide a rationale for future treatment paradigms; and allow physicians to assess adherence to institutional clinical practice guidelines, validate current standardized definitions for patients with invasive fungal infections and promote change where appropriate.

Gender, height, weight, ethnicity, antifungal treatment, fungal colonization, laboratory results, past medical history, invasive fungal infection diagnosis, medications, outcomes
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients with funal infections
Fungal Infection
Not Provided
patients with funal infections
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
172
August 2012
August 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • All patients with a diagnosis of proven or probable invasive fungal infection . This includes patients with proven or probable invasive mold infections as well as patients with proven candidemia.

Exclusion Criteria:

  • All patients with a diagnosis of possible invasive fungal infection . This includes patients with possible mold infections as well as patients with possible candidemia.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00177944
IRB # 0503062
Yes
University of Pittsburgh
University of Pittsburgh
Astellas Pharma US, Inc.
Principal Investigator: Fernanda Silveira, MD University of Pittsburgh
University of Pittsburgh
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP